New heparin dosing recommendations for patients with acute coronary syndromes (Q28184399)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11382373%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

review article

1 reference

title

New heparin dosing recommendations for patients with acute coronary syndromes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11382373%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

1 reference

acute coronary syndrome

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11382373%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

Judith S Hochman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11382373%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

author name string

V Menon

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11382373%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

E M Antman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11382373%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

R M Fuchs

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11382373%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

language of work or name

English

0 references

publication date

1 June 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11382373%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Medicine

8 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11382373%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

volume

110

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11382373%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11382373%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

page(s)

641-650

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11382373%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: Results of GUSTO-I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the M

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Heparin kinetics determined by three assay methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Heparin kinetics in venous thrombosis and pulmonary embolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Glycoprotein IIb/IIIa integrin blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Erroneous activated partial thromboplastin time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Unsuitability of evacuated tubes for monitoring heparin therapy by activated partial thromboplastin time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT). Implications in heparin monitoring by APTT.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. The Investigators of the I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Heparin dosing in patients undergoing coronary intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Adequate Anticoagulation During Cardiopulmonary Bypass Determined by Activated Clotting Time and the Appearance of Fibrin Monomer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Vascular complications after balloon and new device angioplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Bleeding complications with platelet glycoprotein IIb/IIIa receptor antagonists.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Adequate heparinization during PTCA: assessment using activated clotting times

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Heparin kinetics: variables related to disposition and dosage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease. Antithrombotic Therapy Consortium Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

A new regimen for heparin use in acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Predictors for heparin resistance in patients undergoing coronary artery bypass grafting.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Measurement of the activated partial thromboplastin time from a capillary (fingerstick) sample of whole blood. A new method for monitoring heparin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Computer-assisted dosing of heparin. Management with a pharmacy-based anticoagulation service

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Automated heparin-delivery system to control activated partial thromboplastin time: evaluation in normal volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Antithrombotic therapy for venous thromboembolic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

A comparison of reteplase with alteplase for acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events i

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900715-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(01)00715-X

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11382373%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

1 reference